Mylan announced the launch of Voriconazole for Oral Suspension, the generic version of Pfizer’s Vfend for Oral Suspension.

Voriconazole is a triazole antifungal indicated for invasive aspergillosis, nonneutropenic candidemia, candida infections in abdomen, kidney, bladder, wounds, or skin (disseminated), esophageal candidiasis, and serious infections caused by Scedosporium apiospermum and Fusarium species in patients refractory to, or intolerant of, other agents.

RELATED: Infectious Diseases Resource Center

Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity.

RELATED: Fungal Infections

Voriconazole for Oral Suspension is available in a 40mg/mL dosage strength.

For more information call (800) RX-MYLAN or visit